The subject matter of the present invention is a composition for topical application in a subject containing: - hydrogen peroxide, - at least one polyol, - at least one polymer, whereby the at least one polymer is selected from sodium hyaluronate, polyacrylic acid (carbomer), xanthan gum or a blend thereof, and - water. Furthermore, the subject matter of the present invention is an inventive composition for use in the oropharyngeal region.
A61K 8/81 - Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
The present invention relates to a composition for topical application to a subject, comprising: - hydrogen peroxide, - at least one polyol, - at least one polymer, the at least one polymer being selected from sodium hyaluronate, polyacrylic acid (carbomer), xanthan or a mixture thereof, and - water. The present invention also relates to a composition according to the invention for application in the mouth and pharyngeal cavity.
A61K 8/81 - Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
The present invention inter alia relates to a method of promoting collateral circulation comprising the step of exposing a subject to a therapeutically effective amount of an NO donor wherein the therapeutically effective amount of the NO donor promotes arteriogenesis sufficient to augment collateral circulation in a physiological or pathological condition.
A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
A61K 31/34 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
The present invention relates to a composition comprising eucalyptus oil and sweet orange oil for use in a method for the treatment of a viral infection.
The invention relates, in a first aspect, to compositions for the prevention and/or treatment of urinary tract infections and to corresponding medicinal products. In another aspect, the invention relates to compositions containing mannose, to cosmetic products comprising an embodiment of these compositions, and to their external application to the skin. The invention further relates to dispensers which comprise the compositions or cosmetic products according to the invention.
The present application relates to a pharmaceutical preparation comprising (a) from 0.15 to 3 weight percent of glyceryl trinitrate, (b) from 40 to 95 weight percent water, and (c1) from 2 to 10 weight percent of at least one water soluble polymer, or (c2) from 1 to 10 weight percent of at least one water soluble polymer and 5 to 20 weight percent of ethanol.
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
The present invention pertains to a short acting NO donor for use in a method of reducing side effects of a treatment with said short acting NO donor, comprising administering during a defined time period a gradually increasing amount of said short acting NO donor in an intermitting manner. The present invention is further directed to a short acting NO donor for use in a method for the prevention or treatment of an arterial insufficiency, wherein the NO donor is administered in an intermitting manner, and wherein during the initial phase of the administration, the amount of said short acting NO donor is gradually increased.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/00 - Medicinal preparations containing organic active ingredients
A61K 31/21 - Esters, e.g. nitroglycerine, selenocyanates
A61K 31/34 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
The present invention pertains to a short acting NO donor for use in a method of reducing side effects of a treatment with said short acting NO donor, comprising administering during a defined time period a gradually increasing amount of said short acting NO donor in an intermitting manner. The present invention is further directed to a short acting NO donor for use in a method for the prevention or treatment of an arterial insufficiency, wherein the NO donor is administered in an intermitting manner, and wherein during the initial phase of the administration, the amount of said short acting NO donor is gradually increased.
A61K 31/00 - Medicinal preparations containing organic active ingredients
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/21 - Esters, e.g. nitroglycerine, selenocyanates
A61K 31/34 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
9.
Induction of arteriogenesis with an NO (nitric oxide) donor
The present invention inter alia relates to a method of promoting collateral circulation comprising the step of exposing a subject to a therapeutically effective amount of an NO donor wherein the therapeutically effective amount of the NO donor promotes arteriogenesis sufficient to augment collateral circulation in a physiological or pathological condition.
A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
A61K 31/34 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
10.
Use of stabilized granules containing glyceryl trinitrate for arteriogenesis
The present invention inter alia relates to a method of treating or preventing an arterial insufficiency, where an NO donor is administered in an intermitting manner to a subject in an amount of effective for the induction of arteriogenesis, and wherein the NO donor is a solid pharmaceutical preparation with the active substance glyceryl trinitrate for oromucosal or oral administration characterized in that it contains between 0.05 and 2 weight % glyceryl trinitrate (GTN), at least one diluent, one carrier material, and at least one substance that reduces the volatility of GTN, whereby this substance is a non-volatile ester stabilizer whose melting point is not higher than 60° C.
A61K 31/21 - Esters, e.g. nitroglycerine, selenocyanates
A61K 31/34 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
A61K 31/616 - Salicylic acidDerivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Solid pharmaceutical preparation with the active substance glyceryl trinitrate for oromucosal or oral administration characterized in that it contains between 0.05 and 2 weight % glyceryl trinitrate, at least one carrier material, and at least one substance that reduces the volatility of the GTN, whereby this substance is a non-volatile ester stabilizer.
The present application relates to a pharmaceutical preparation comprising (a) from 0.15 to 3 weight percent of glyceryl trinitrate, (b) from 40 to 95 weight percent water, and (c1) from 2 to 10 weight percent of at least one water soluble polymer, or (c2) from 1 to 10 weight percent of at least one water soluble polymer and 5 to 20 weight percent of ethanol.
The invention relates to a syringe with a Luer lock connector (5) for attaching a corresponding first connection tube part to a terminal discharge channel opening (3) for dispensing the content of the syringe, which opening is formed on an attachment tube portion (2) integrally formed on the distal end of the housing (1) and surrounding an attachment channel (4), on the inner wall of which attachment tube portion (2) the Luer lock connector (5) is integrally formed, wherein an outer wall (6) of the attachment tube portion (2) is designed as a truncated attachment cone (7), tapering at least in part in the direction of the distal end, for optional connection to a corresponding second connection tube part.
Solid pharmaceutical preparation with the active substance glyceryl trinitrate for oromucosal or oral administration characterized in that it contains between 0.05 and 2 weight % glyceryl trinitrate, at least one carrier material, and at least one substance that reduces the volatility of the GTN, whereby this substance is a non-volatile ester stabilizer.
The present invention inter alia relates to a method of treating or preventing an arterial insufficiency, wherein an NO donor is administered in an intermitting manner to a subject in an amount effective for the induction of arteriogenesis, and wherein the NO donor is a solid pharmaceutical preparation with the active substance glyceryl trinitrate for oromucosal or oral administration characterized in that it contains between 0.05 and 2 weight % glyceryl trinitrate (GTN), at least one diluent, one carrier material, and at least one substance that reduces the volatility of GTN, whereby this substance is a non-volatile ester stabilizer whose melting point is not higher than 60° C.
A61K 31/34 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
A61K 31/616 - Salicylic acidDerivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
The present invention inter alia relates to a method of promoting collateral circulation comprising the step of exposing a subject to a therapeutically effective amount of an NO donor wherein the therapeutically effective amount of the NO donor promotes arteriogenesis sufficient to augment collateral circulation in a physiological or pathological condition.
A61K 31/34 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 33/00 - Medicinal preparations containing inorganic active ingredients
A61P 9/00 - Drugs for disorders of the cardiovascular system
18.
STABILIZED GRANULES CONTAINING GLYCERYL TRINITRATE FOR INDUCING ARTERIOGENESIS
The present invention inter alia relates to a method of treating or preventing an arterial insufficiency, wherein an NO donor is administered in an intermitting manner to a subject in an amount effective for the induction of arteriogenesis, and wherein the NO donor is a solid pharmaceutical preparation with the active substance glyceryl trinitrate for oromucosal or oral administration characterized in that it contains between 0.05 and 2 weight% glyceryl trinitrate (GTN), at least one diluent, one carrier material, and at least one substance that reduces the volatility of GTN, whereby this substance is a non-volatile ester stabilizer whose melting point is not higher than 60 °C.
A61K 31/21 - Esters, e.g. nitroglycerine, selenocyanates
A61K 31/34 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
The present invention inter alia relates to a method of promoting collateral circulation comprising the step of exposing a subject to a therapeutically effective amount of an NO donor wherein the therapeutically effective amount of the NO donor promotes arteriogenesis sufficient to augment collateral circulation in a physiological or pathological condition.
A61K 31/34 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 33/00 - Medicinal preparations containing inorganic active ingredients
A61P 9/00 - Drugs for disorders of the cardiovascular system
The invention relates to an atomiser for a liquid, in particular a pocket atomiser (10) for acute treatment of angina pectoris with a nitroglycerin solution, comprising a container (12) receiving the liquid, and a metering and spray device (16) that has a suction tube (32) immersed in the liquid. In order, in particular in the case of a container (12) having a convexly upwardly arched base (20), reliably to prevent the lower end of the suction tube (32) from becoming positioned on the container base (20) and a resulting blockage of a suction opening (62) of the suction tube (32), according to the invention the atomiser (10) comprises a diverter element (64) fastened to the suction tube (32) or to another part of the metering and spray device (16). Irrespective of the particular orientation of the atomiser (10) the diverter element (64) exerts a force on the suction tube (32) in a constant direction and bends same to one side.
Solid pharmaceutical preparation with the active substance glyceryl trinitrate for oromucosal or oral administration characterized in that it contains between 0.05 and 2 weight% glyceryl trinitrate, at least one carrier material, and at least one substance that reduces the volatility of the GTN, whereby this substance is a non-volatile ester stabilizer.
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Solid pharmaceutical preparation with the active substance glyceryl trinitrate for oromucosal or oral administration characterized in that it contains between 0.05 and 2 weight% glyceryl trinitrate, at least one carrier material, and at least one substance that reduces the volatility of the GTN, whereby this substance is a non-volatile ester stabilizer.
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
23.
PACKAGING OF SOLID PHARMACEUTICAL PREPARATIONS CONTAINING THE ACTIVE SUBSTANCE GLYCERYL TRINITRATE
Solid pharmaceutical preparation containing the active substance glyceryl trinitrate in the form of a single dose for sublingual or oral administration, which is packaged in a composite film, wherein the composite film contains a layer comprising polyacrylonitrile (PAN) on the side facing the preparation.
A61K 31/21 - Esters, e.g. nitroglycerine, selenocyanates
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Disclosed are methods of treatment and compositions containing at least one non-volatile silicone oil in combination with at least one spreading agent for use in the treatment of skin conditions in mammals typified by scales, plaques and scabs and associated with punctiform bleeding during the removal of scales, plaque or scabs. Preferred conditions are selected from the group consisting of seborrheic dermatitis, psoriasis, and cradle cap wherein the incidence of punctiform bleeding and formation of bloody tear points on the skin during removal of the scales is diminished or prevented.
The invention relates to a composition for killing ectoparasites and/or the eggs thereof, said composition containing a volatile, unpolar, organic solvent that is liquid at room temperature, between 1 and 10 wt. % of at least one spreading agent, and between 35 and 65 wt. %, respectively in relation to the whole composition, of at least one polysiloxane having a viscosity higher than 90 cSt.
A01N 27/00 - Biocides, pest repellants or attractants, or plant growth regulators containing hydrocarbons
A01N 55/10 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen and sulfur containing silicon
The invention relates to an applicator (2) for applying a product, in particular a delousing agent based on Dimeticon, comprising a housing (4) having an application side (6) and a connection side (8), at least one application body (10) having an application channel (12) extending therein, and an outlet opening (14) connected thereto and at least two comb teeth (16). The application body (10) extends from the application side (6) of the housing (4). The comb teeth (16) are spaced apart from each other and are disposed on an end facing away from the application side (6) of the housing (4), forming at least one intermediate space, thereby enclosing an outlet opening (14). The connection side (8) comprises an inlet (18) for introducing the product into the application body (10) and a connection device (20) for connecting the housing (4) to a product container. The applicator (2) is particularly able to apply a product having a viscosity in a range between 2 and 200 mPas, especially in a range between 5 and 20 mPas, and in particular in a range between 13 and 15 mPas, and can be used particularly effectively for treating lice with a delousing agent based on Dimeticon.
A45D 19/02 - Hand-actuated implements, e.g. hand-actuated spray heads
A61K 31/80 - Polymers containing hetero atoms not provided for in groups
A01N 55/00 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen and sulfur
29.
Long-term stable pharmaceutical preparation containing the active ingredient glyceryl trinitrate
A pharmaceutical preparation containing the active substance glyceryl trinitrate having improved storage stability in a container. The improved storage stability is achieved by the addition of a proton-absorbing substance either as part of the preparation as placed into the container or applied to the surface of the preparation's storage container before the remaining components of the preparation are placed into the container. The preparation can preferably be filled into a plastic bottle having a spray pump.
The present invention relates to a pharmaceutical preparation, comprising a mixture of at least one pharmaceutical active ingredient, at least one alcohol component and at least one triglyceride component, in a plastic container, characterized in that the plastic has a water vapor permeability of no more than 3.0 g/m2/24h (measured on a film 100 μm thick at 40°C and 90% relative humidity).
The invention relates to a pharmaceutical composition containing the active ingredient glycerol trinitrate having improved storage stability in a container. The improved storage stability is achieved by adding a substance absorbing protons, which is added to the composition, or applied to the surfaces of the container coming in contact with the product. The composition is preferably filled into a plastic bottle having a spray pump.
The invention relates to a pharmaceutical composition containing the active ingredient glycerol trinitrate having improved storage stability in a container. The improved storage stability is achieved by adding a substance absorbing protons, which is added to the composition, or applied to the surfaces of the container coming in contact with the product. The composition is preferably filled into a plastic bottle having a spray pump.
The invention pertains to compositions for combating ectoparasites, in particular head lice, as well as their eggs (nits). The compositions comprise a linear polysiloxane having a viscosity ឬ 10 cSt and a linear siloxane having a viscosity ᡶ 90 cSt, whereby dimeticones are preferred polysiloxanes.
A01N 55/10 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen and sulfur containing silicon
A01P 15/00 - Biocides for specific purposes not provided for in groups
A01N 25/30 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests characterised by the surfactants
34.
COMPOSITION FOR COMBATING ECTOPARASITES AND THEIR OVA
A composition for killing ectoparasites and/or their ova. The composition contains 30-49% by weight of the composition of a low viscosity linear polysiloxane having a viscosity less than 10 cSt, 35 to 65% by weight of the composition of a higher viscosity linear polysiloxane having a viscosity greater than 90 cSt, and at least one spreading agent.
patents
